Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merus stock logo
MRUS
Merus
$41.97
+2.8%
$45.03
$18.21
$52.03
$2.46B1.1575,478 shs741,283 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.98
$3.01
$1.79
$4.70
$393.24M1.57797,072 shs2.97 million shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$4.83
-5.8%
$5.64
$2.13
$7.73
$232.84M1.28559,558 shs365,894 shs
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merus stock logo
MRUS
Merus
+0.91%+1.27%-11.13%+20.95%+95.78%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
+0.34%+4.20%+14.18%-16.06%+44.66%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-0.77%+0.59%-3.75%+2.60%+84.53%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merus stock logo
MRUS
Merus
2.996 of 5 stars
4.53.00.00.02.71.70.0
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.0453 of 5 stars
3.33.00.04.30.62.51.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
2.8194 of 5 stars
3.52.00.00.02.03.31.3
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merus stock logo
MRUS
Merus
3.00
Buy$56.3334.22% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.67
Moderate Buy$4.8362.19% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.0044.93% Upside
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest ORGO, PBYI, MRUS, and PGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Merus stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/11/2024
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00
3/28/2024
Merus stock logo
MRUS
Merus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$69.00
3/4/2024
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $65.00
3/1/2024
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$5.00
3/1/2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
2/29/2024
Merus stock logo
MRUS
Merus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $65.00
2/29/2024
Merus stock logo
MRUS
Merus
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $65.00
2/29/2024
Merus stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$49.00 ➝ $58.00
2/13/2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
2/7/2024
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merus stock logo
MRUS
Merus
$43.95M56.05N/AN/A$6.17 per share6.80
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$433.14M0.91$0.22 per share13.81$2.11 per share1.41
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$235.64M0.99$0.65 per share7.43$1.12 per share4.31
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$34.99M10.15N/AN/A$0.54 per share7.59

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merus stock logo
MRUS
Merus
-$154.94M-$3.04N/AN/AN/A-352.56%-50.61%-37.56%5/2/2024 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M$0.0474.52N/A1.14%1.81%1.09%5/9/2024 (Confirmed)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.4610.5016.662.949.16%58.21%10.40%5/2/2024 (Confirmed)
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/A

Latest ORGO, PBYI, MRUS, and PGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-$0.03N/A+$0.03N/AN/AN/A  
5/2/2024N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-$0.16N/A+$0.16N/AN/AN/A  
2/29/2024Q4 2023
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.33$0.26-$0.07$0.26$73.22 million$72.20 million
2/28/2024Q4 2023
Merus stock logo
MRUS
Merus
-$0.71-$1.09-$0.38-$1.09$10.43 million$8.94 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merus stock logo
MRUS
Merus
N/A
5.34
5.34
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.22
2.80
2.44
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
1.23
1.57
1.50
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.99
2.12
2.12

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Merus stock logo
MRUS
Merus
96.14%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
70.96%

Insider Ownership

CompanyInsider Ownership
Merus stock logo
MRUS
Merus
4.30%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
34.00%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
22.70%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
4.26%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Merus stock logo
MRUS
Merus
17258.69 million56.16 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
862131.96 million87.10 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
18548.21 million37.26 millionOptionable
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
7986.60 millionN/AOptionable

ORGO, PBYI, MRUS, and PGNX Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Merus logo

Merus

NASDAQ:MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Organogenesis logo

Organogenesis

NASDAQ:ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Puma Biotechnology logo

Puma Biotechnology

NASDAQ:PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Progenics Pharmaceuticals logo

Progenics Pharmaceuticals

NASDAQ:PGNX
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.